Korean J Hematol.  2011 Sep;46(3):148-150. 10.5045/kjh.2011.46.3.148.

Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent(R) Technology

• Matsushita T

• KMID: 2251994
• DOI: http://doi.org/10.5045/kjh.2011.46.3.148

Abstract

No abstract available.

MeSH Terms

Antibodies
Antibodies

Figure

• 

  Fig. 1 Comparison between conventional and defucosylated antibodies. (A) Comparison of ADCC: In vitro ADCC of conventional (circle) and defucosylated (square) rituximab was compared. (B) Comparison of oligosaccharide profile: The percentage of rituximab produced by using conventional CHO cells and that produced by the FUT8-/- CHO cells was compared. Fucosylated oligosaccharides were not detected in the FUT8-/- CHO-produced ritumixab.

Reference

1. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001; 276:6591–6604. PMID: 11096108.

2. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006; 103:4005–4010. PMID: 16537476.

3. Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999; 17:176–180. PMID: 10052355.

4. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003; 278:3466–3473. PMID: 12427744.

5. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004; 64:2127–2133. PMID: 15026353.

6. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 2004; 87:614–622. PMID: 15352059.

7. Duvic M, Pinter-Brown L, Foss FM, et al. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Blood. 2010; 116:abst 962.

8. Ishida T, Joh T, Uike N, et al. Multicenter phase II study of KW-0761, a defucosylated anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma (ATL). Blood. 2010; 116:abst 285.